Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer.
about
Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patientsLong-Term Partial Remission with Capecitabine/Trastuzumab in a Patient with Metastatic Breast Cancer Following Progression on Trastuzumab AloneDrug rechallenge and treatment beyond progression--implications for drug resistance.Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast CancerRisk factors for disease progression in HER2-positive breast cancer patients based on the location of metastases.Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians.Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer.Trastuzumab and lapatinib beyond trastuzumab progression for metastatic breast cancer: strategies and pitfalls.HER2 as a target for breast cancer therapy.Management of metastatic HER2-positive breast cancer progression after adjuvant trastuzumab therapy - current evidence and future trends.Treatment of metastatic breast cancer: second line and beyond.Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge.Trastuzumab: unusual responses and toxicities.Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma.Usefulness of docetaxel as first-line chemotherapy for metastatic extramammary Paget's disease.Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study.Clinical outcomes and cardiac safety of continuous antiHer2 therapy in c-erbB2-positive metastatic breast cancer patients.Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer
P2860
Q33644305-2170ADB1-F5CD-41DF-BFDB-1C94A4E7F1D3Q35909554-8C4AA5C4-5377-4356-9E59-97AE40E7A84EQ35967416-89593422-CE5E-491F-B4EC-91DE80161389Q35977527-557FE3D0-7099-43E5-8065-286DC91AFBDFQ36181895-480B1BDA-8E4D-4706-9A32-4AAC8576BB38Q37236305-0664F88D-617F-40E8-AD93-390A9344E5C3Q37360162-CFB95F4A-A3CB-49A9-92E8-DFF800254499Q37687375-50C7959E-04DC-4FFD-8011-D5B93BB35FEDQ37705396-3DAAA799-79C7-4679-BB0A-6C5F5FAFD30DQ37725973-9960C4B2-B645-4FFF-9D58-E50D5F880F28Q37802108-14BB4EF2-30D6-4D1F-AD91-6FC02F6704DDQ38892820-EAD8E062-62C7-41F1-8CC7-90EB1EE58E0BQ39957050-D0971466-665C-4963-BC39-CD48BFD9D51EQ40189187-F2C886E4-8D2F-4F37-A47F-F8FBA1B8F92DQ40279396-7C903B2A-92BF-470B-AD36-1F5DFA362B76Q46074968-0DCC276F-C564-40C4-8617-4CD078DB5104Q54368881-4A6E1DD0-1A8A-418A-B1C5-DB3A82B970CDQ58849543-26A3F74A-C8F2-4A49-9DF8-007AB85D5C3E
P2860
Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Continuing trastuzumab beyond ...... with metastatic breast cancer.
@en
type
label
Continuing trastuzumab beyond ...... with metastatic breast cancer.
@en
prefLabel
Continuing trastuzumab beyond ...... with metastatic breast cancer.
@en
P2093
P2860
P356
P1476
Continuing trastuzumab beyond ...... with metastatic breast cancer
@en
P2093
Diego D'Agostino
Emilia Montagna
Giuseppe Cancello
Giuseppe Di Lorenzo
Mario Giuliano
Monica Plaitano
Sabino De Placido
P2860
P2888
P356
10.1186/BCR2119
P577
2008-07-16T00:00:00Z
P5875
P6179
1011963954